Amber Young1, Dinesh Khanna. 1. aDivision of Rheumatology/Department of Internal Medicine, University of Michigan bDivision of Rheumatology/Department of Internal Medicine, University of Michigan Scleroderma Program, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: To review pharmacologic and nonpharmacologic therapies in the treatment of systemic sclerosis (SSc) from 2011 to 2014 through a systematic review. RECENT FINDINGS: Our systematic review identifies randomized controlled trials, meta-analyses, systematic reviews, case series, and observational studies which support organ-based therapy with known immunosuppressive agents, novel agents, and hematopoietic stem cell transplantation, and also includes nonpharmacologic therapies improving visceral and physical function. SUMMARY: SSc is an orphan autoimmune disorder with significant morbidity and mortality. Although there has been significant progress over the years in therapeutic options for SSc, the mainstays of treatment are organ-based and primarily symptom management. Our systematic review of the last 4 years of treatment emphasizes known treatment strategies already in practice, but also identifies new therapeutic approaches with additional biologic agents and hematopoietic stem cell transplantation.
PURPOSE OF REVIEW: To review pharmacologic and nonpharmacologic therapies in the treatment of systemic sclerosis (SSc) from 2011 to 2014 through a systematic review. RECENT FINDINGS: Our systematic review identifies randomized controlled trials, meta-analyses, systematic reviews, case series, and observational studies which support organ-based therapy with known immunosuppressive agents, novel agents, and hematopoietic stem cell transplantation, and also includes nonpharmacologic therapies improving visceral and physical function. SUMMARY: SSc is an orphan autoimmune disorder with significant morbidity and mortality. Although there has been significant progress over the years in therapeutic options for SSc, the mainstays of treatment are organ-based and primarily symptom management. Our systematic review of the last 4 years of treatment emphasizes known treatment strategies already in practice, but also identifies new therapeutic approaches with additional biologic agents and hematopoietic stem cell transplantation.
Authors: Lorinda Chung; Christopher P Denton; Oliver Distler; Daniel E Furst; Dinesh Khanna; Peter A Merkel Journal: Clin Exp Rheumatol Date: 2012-05-30 Impact factor: 4.473
Authors: M O Becker; A Schohe; K Weinert; D Huscher; U Schneider; G R Burmester; G Riemekasten Journal: Ann Rheum Dis Date: 2012-06-11 Impact factor: 19.103
Authors: S Prey; K Ezzedine; A Doussau; A-S Grandoulier; D Barcat; E Chatelus; E Diot; C Durant; E Hachulla; J-D de Korwin-Krokowski; E Kostrzewa; T Quemeneur; C Paul; T Schaeverbeke; J Seneschal; A Solanilla; A Sparsa; S Bouchet; S Lepreux; F-X Mahon; G Chene; A Taïeb Journal: Br J Dermatol Date: 2012-10-05 Impact factor: 9.302
Authors: N Del Papa; F Onida; E Zaccara; G Saporiti; W Maglione; E Tagliaferri; R Andracco; D Vincenti; T Montemurro; L Mircoli; C Vitali; A Cortelezzi Journal: Bone Marrow Transplant Date: 2016-08-22 Impact factor: 5.483
Authors: Se Yun Cheon; Jong Ho Park; Amir H Ameri; Richard T Lee; Rosalynn M Nazarian; Shadmehr Demehri Journal: J Invest Dermatol Date: 2022-03-25 Impact factor: 7.590
Authors: Femke C C van Rhijn-Brouwer; Hendrik Gremmels; Joost O Fledderus; Timothy R D Radstake; Marianne C Verhaar; Jacob M van Laar Journal: Curr Rheumatol Rep Date: 2016-02 Impact factor: 4.592
Authors: Dinesh Khanna; Vivek Nagaraja; Chi-Hong Tseng; Fereidoun Abtin; Robert Suh; Grace Kim; Athol Wells; Daniel E Furst; Philip J Clements; Michael D Roth; Donald P Tashkin; Jonathan Goldin Journal: Arthritis Res Ther Date: 2015-12-23 Impact factor: 5.156